SalutarisMD to Introduce its New Generation Medical Device for wet AMD Therapy at Ophthalmology Futures European Forum
Today, Salutaris Medical Devices, Inc. (SalutarisMD® ) announced that during its upcoming presentation at the Ophthalmology Futures European Forum on September 8, the Company will introduce its new generation, commercial ready, episcleral brachytherapy applicator system. The presentation by Dr. Laurence Marsteller, CEO, will discuss how the new SalutarisMD system (SMD-DA™) is designed to deliver improved dosimetry to wet AMD lesions and improved ease of use for retinal surgeons. The Company will also display the system at its exhibitor’s booth. ISO audits for certification and CE application are underway and the Company expects to receive ISO 13485 certification and the CE Mark on the commercial product by year end.
The Company recently received US regulatory approval for an upcoming clinical study utilizing the new and improved device. The Company has successfully completed a previous study with a first generation clinical device. While that study was not intended to be extrapolated for statistical significance, individual subject results were tracked. In three of the four treatment-naïve patients and one of the two chronically treated wet AMD patients, best corrected visual acuity (BCVA) improved at two years following SMD-1™ treatment (range: +4 to +25 ETDRS letters). In addition, two treatment-naïve patients did not require any further anti-VEGF injections during the following two years.
As wet AMD is the leading cause of blindness worldwide, there is an urgent and compelling need for new therapies that improve visual outcomes and lower the burden of care. Dr. Laurence Marsteller commented that, “Our new commercial ready applicator system is a significant marker of SalutarisMD’s continued progress and we are looking forward to positively affecting patient outcomes.”
(Caution: Investigational Device, Limited to Investigational Use).
SalutarisMD (Salutaris Medical Devices, Inc. and Salutaris Medical Devices, Ltd.) is a pre-revenue medical device company developing an investigational ophthalmic treatment for wet age-related Macular Degeneration (wet AMD). The SalutarisMD patented technology incorporates a minimally invasive single-use brachytherapy procedure that can be performed in an outpatient setting in approximately 15 minutes. This method delivers localized tissue irradiation that is performed under the direct care and expertise of a retina specialist. For more information visit www.SalutarisMD.com or www.SalutarisMD.co.uk .
About Ophthalmology Futures Forums
Ophthalmology Futures Forums are clinician-driven innovation meetings focusing on technology as well as financing, market access and commercialisation of new ophthalmic products. They cover all aspects of global innovation in ophthalmic devices, diagnostics and pharmaceuticals. For more information visit http://www.ophthalmology-futures.com .
Salutaris Medical Devices, Inc.
4340 N. Campbell Ave. Suite 266
Tucson, AZ 85718
Salutaris Medical Devices, Ltd.
Level 1, Bessemer Building Imperial College
London SW72AZ +44 (0) 203 282 7166
Joanne Vitali, Communications Director
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skrive dig op her og du vil løbende modtage pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
CA-THREATMETRIX18.12.2017 14:02 | pressemeddelelse
ThreatMetrix Exceeds 45% Annual Growth as Organizations Embrace Digital Identity as Must-Have Technology
DWC-3.018.12.2017 11:56 | pressemeddelelse
DWC Secures € 10,8 M From GEM Global
EURID18.12.2017 11:02 | pressemeddelelse
EURid Hosts Green Discussion Panel at The 2017 Internet Governance Forum in Geneva
BEARINGPOINT18.12.2017 10:02 | pressemeddelelse
BearingPoint Achieves Platinum Status in the Salesforce Consulting Partner Program
SES/TIMOR-TELECOM18.12.2017 08:57 | pressemeddelelse
Timor Telecom Enhances International Voice Connections in Timor-Leste Through SES Networks
STEEPER-ENERGY18.12.2017 08:02 | pressemeddelelse
Steeper Energy Announces EUR 50.6 M (DKK 377 M) Advanced Biofuel Project with Norwegian-Swedish joint venture Silva Green Fuel in Licensing Deal
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum